Data / Research funding / Illinois / Iit Research Institute
Iit Research Institute: 12 NIH awards ($15.7M), fiscal years 2021 to 2026
Iit Research Institute in Chicago, IL is funded under 12 NIH awards ($15.7M) in the NIH and NSF award files, read 2026-11-04. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- DGBUFQYMKWB5
- State
- Illinois
Awards
12 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER AND OTHER INDICATIONS INDICATIONS | NIH | National Cancer Institute | 2022 to 2025 | $2,892,988 | April 1, 2022 | March 31, 2026 | MCCORMICK, DAVID L. | reporter.nih.gov |
| Toxicology Studies on Compound MTX-531 | NIH | National Cancer Institute | 2022 to 2025 | $2,361,110 | June 12, 2024 | June 11, 2025 | MCCORMICK, DAVID L. | reporter.nih.gov |
| Task D8: Nonclinical Services for Interventional Agents against SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,883,524 | May 1, 2018 | April 30, 2025 | JOHNSON, WILLIAM | reporter.nih.gov |
| PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV | NIH | National Cancer Institute | 2021 to 2024 | $1,847,366 | September 8, 2020 | March 31, 2025 | MCCORMICK, DAVID | reporter.nih.gov |
| NON-CLINICAL SAFETY OF PTH-IA, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,742,775 | September 16, 2020 | July 8, 2024 | HORN, THOMAS | reporter.nih.gov |
| Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013 | NIH | National Cancer Institute | 2022 to 2023 | $1,460,690 | September 22, 2023 | May 21, 2024 | MCCORMICK, DAVID | reporter.nih.gov |
| PTTP TASK ORDER - IITRI - MS RODENT AND NON-RODENT MTD-DRF STUDIES | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,434,434 | September 26, 2025 | September 25, 2026 | reporter.nih.gov | |
| LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial, | NIH | National Cancer Institute | 2021 to 2023 | $1,262,892 | September 17, 2018 | March 16, 2024 | MCCORMICK, DAVID | reporter.nih.gov |
| FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS | NIH | National Institute on Drug Abuse | 2024 | $512,266 | September 18, 2024 | February 10, 2025 | HORN, THOMAS | reporter.nih.gov |
| IGF::OT::IGF NExT Preclinical Toxicology & Pharmacology of Drugs Developed for Cancer Patients, TO#3, Exploratory Studies of CCR4 CART Cells | NIH | National Cancer Institute | 2021 | $238,571 | September 8, 2017 | December 31, 2021 | MCCORMICK, DAVID | reporter.nih.gov |
| Contract Orientation and Kickoff Meeting | NIH | National Cancer Institute | 2024 | $9,383 | January 25, 2024 | March 24, 2024 | MCCORMICK, DAVID L. | reporter.nih.gov |
| Pre-Clinical Models of Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $5,000 | July 15, 2024 | July 14, 2031 | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 3 | $1,165,045 | 0 | $0 |
| 2024 | 8 | $4,974,757 | 0 | $0 |
| 2023 | 4 | $4,807,106 | 0 | $0 |
| 2022 | 5 | $3,084,493 | 0 | $0 |
| 2021 | 4 | $1,619,598 | 0 | $0 |
Topics of its NIH awards
- Cancer
- Prevention
- Biotechnology
- Immunization
- Cardiovascular
- Colo-Rectal Cancer
- Digestive Diseases
- Genetics
- Women's Health
- Prostate Cancer
- Urologic Diseases
- Vaccine Related
Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.